Most recent update: Friday, June 8, 2018 - 12:16

Bariatric News - Cookies & privacy policy

You are here

Israeli reimbursement

EndoBarrier gains reimbursement coverage in Israel

T2DM patients with obesity could receive reimbursement for at least 50% for EndoBarrier Therapy.

One of Israel’s largest health maintenance organisations (HMOs), Clalit Health Services, has established a reimbursement coverage policy for EndoBarrier Therapy, an endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity.

According to the Israel Diabetes Association, there are an estimated 600,000 Israeli adults currently living with diabetes, and approximately one-third of these are undiagnosed.

“Achieving this reimbursement in Israel follows our recent preliminary reimbursement code in the Netherlands and NUB Status 1 reimbursement designation in Germany, reinforcing the strategic impact of our foundational approach to reimbursement-driven markets,” said Stuart A Randle, president and CEO of GI Dynamics. “We are pleased that one of the world’s largest and most progressive HMOs has become the first organisation to widely adopt our innovative technology, underscoring the clinical and economic value of EndoBarrier Therapy in treating type 2 diabetes and obesity. We will continue to work closely with Clalit and Medison, our distributor in this region, to make EndoBarrier more broadly available to physicians and patients in Israel."

The coverage policy entitles participating hospitals in Israel to negotiate with Clalit Health Services on the total charge for EndoBarrier Therapy. Speficially, patients with type 2 diabetes and obesity who are insured by Clalit Health Services and enrolled in the Mushlam supplementary insurance plan are eligible to receive reimbursement for at least 50% of the total agreed-upon charge for EndoBarrier Therapy.

"We are extremely pleased to partner with GI Dynamics to bring people living with uncontrolled diabetes and obesity greater access to what we believe is a highly effective, less invasive procedure to lower blood sugar and reduce weight," said Meir Jacobsohn, CEO of Medison. "We have already seen a significant demand for EndoBarrier Therapy among Israeli men and women with these conditions. We are pleased with this reimbursement decision from Clalit, which will now make EndoBarrier Therapy a more accessible treatment option for people to improve their health and quality of life."

The EndoBarrier received medical device registration approval from the Israeli Ministry of Health in February 2012 for the treatment of type 2 diabetes and obesity for up to 12 months. It is also approved for use in Europe and Australia, as well as by a growing number of countries in South America and the Middle East. More than 1,300 patients worldwide have been treated with EndoBarrier Therapy.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.

EndoBarrier Gastrointestinal Liner

1 year 6 months ago
2 years 3 months ago
2 years 8 months ago
2 years 10 months ago
3 years 2 days ago
3 years 2 weeks ago
3 years 3 months ago
3 years 6 months ago
3 years 8 months ago
3 years 9 months ago
4 years 2 months ago
4 years 2 months ago
4 years 4 months ago
4 years 6 months ago
4 years 9 months ago
4 years 10 months ago
4 years 11 months ago
4 years 12 months ago
5 years 4 hours ago
5 years 1 month ago
5 years 5 months ago
5 years 7 months ago
5 years 7 months ago
5 years 9 months ago
5 years 11 months ago
6 years 10 months ago
7 years 5 months ago